Thymosin Alpha-1
A 28-amino-acid immunomodulatory peptide studied for T-cell enhancement, antiviral immunity, and immune support across multiple research contexts.
Molecular Structure
Amino Acid Sequence
Molecular Formula
Molecular Weight
Half-Life
CAS Number
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from bovine thymic tissue in 1972 by Allan Goldstein and colleagues. It is one of several thymic peptides that play roles in T-cell maturation and immune function, and is naturally produced from a larger precursor protein (prothymosin alpha) through enzymatic processing. The peptide is found in highest concentrations in thymic tissue but also detectable in spleen, lung, kidney, and circulating blood. Synthetic Tα1 was developed under the trade name Zadaxin and has been studied for more than four decades.
Thymosin Alpha-1 is notable in research for its immunomodulatory properties, with documented effects on T-cell function and other immune cells without producing broad pro-inflammatory effects of cytokines or the suppressive effects of immunosuppressants. The peptide is approved in more than 30 countries (including Italy, China, and India) for treatment of chronic hepatitis B, chronic hepatitis C, and as an adjuvant to influenza vaccines, though it has not received FDA approval in the United States. It holds FDA orphan drug designations for several indications including hepatitis B, malignant melanoma, and DiGeorge syndrome.
Mechanism of action
Thymosin Alpha-1’s mechanisms of action have been investigated across multiple pathways:
- Toll-like receptor signaling: The peptide acts primarily through Toll-like receptors (TLRs), particularly TLR9 in plasmacytoid dendritic cells and TLR2 in conventional dendritic cells, triggering downstream signaling through MyD88 and other adapter proteins.
- T-cell differentiation and function: Research has documented promotion of T-cell maturation from progenitor cells in the thymus and enhancement of mature T-cell function in peripheral tissues, including cytotoxic T-cell activity and Th1 cytokine production.
- Natural killer cell enhancement: Studies have shown effects on natural killer (NK) cell number and cytotoxic activity, contributing to enhanced innate immune surveillance against virally infected and transformed cells.
- Modulation of inflammatory pathways: Tα1 modulates inflammatory cytokine production with context-dependent effects, generally enhancing antiviral and antitumor cytokine production while moderating excessive inflammatory responses.
- Dendritic cell maturation: Research has documented effects on dendritic cell maturation and antigen-presenting function, bridging innate and adaptive immune responses.
These pathways are characterized in both preclinical models and human clinical research.
Research applications
Thymosin Alpha-1 has been investigated across several research domains, with the most active areas including:
- Chronic hepatitis B research: Tα1 has been studied extensively in chronic hepatitis B, where research has examined enhancement of host immune response to clear hepatitis B virus, particularly in combination with other antiviral therapies. Trials have demonstrated improvements in viral control markers.
- Sepsis research: Sepsis is increasingly recognized as a condition of dysregulated immunity, often with immunosuppressive phases that contribute to mortality. Multiple clinical trials have examined Tα1 in severe sepsis populations, with research examining effects on immune restoration.
- Vaccine adjuvant research: Tα1 has been studied and used as an adjuvant to influenza vaccines, particularly in elderly populations where immune responses to vaccination are typically reduced.
- Cancer immunotherapy research: Studies have examined Tα1 as an adjunct to cancer therapy, particularly in malignant melanoma (where it holds FDA orphan drug designation) and various other malignancies, with mechanisms focused on enhancing antitumor immune responses.
- COVID-19 research: During the pandemic, Tα1 was examined as a potential treatment to enhance antiviral immunity, with several studies suggesting potential benefit in selected severe COVID-19 populations.
This compound is intended for laboratory research use only. It has not been approved for human therapeutic use by any regulatory agency.
Storage & reconstitution
In its lyophilized form, Thymosin Alpha-1 tolerates ambient temperatures during shipping but should be stored long-term at -20°C, protected from light. Properly stored lyophilized peptide remains stable for 24 months or longer.
Once reconstituted with bacteriostatic water for injection, Thymosin Alpha-1 solutions should be stored refrigerated at 2-8°C and used within 28 days. Avoid repeated freeze-thaw cycles, which can degrade peptide structure and reduce activity.
Visual inspection should be performed before each use. The reconstituted solution should be clear and colorless. Reject any solution that appears cloudy, discolored, or contains visible particulate matter.
For step-by-step reconstitution calculations, see our reconstitution calculator.
For laboratory research use only. The compound described on this page is intended exclusively for in vitro research and laboratory experimentation by qualified researchers and is not for human or veterinary use. It is not a drug, food, dietary supplement, or cosmetic, and has not been approved by the FDA, Health Canada, EMA, or any other regulatory authority for the diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition. The information provided on this page is for educational and reference purposes only and does not constitute medical advice. By accessing this content you confirm that you are a qualified researcher purchasing for legitimate laboratory purposes.